Shares in Sequenom dropped 11.3 percent for the five-day trading period ended Tuesday. It marked the third week in a row the firm’s shares have declined, and followed last week’s 9.2 percent drop. There had been no recent news regarding the company — though it did report after Tuesday that it had received commitments from institutional investors to buy a total of 6,666,666 shares of Sequenom for $3 per share.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.